What is the Tango Therapeutics Inc. stock price forecast?

Tango Therapeutics Inc. is currently trading at $25.85. View real-time AI analysis on Alpha Lenz.

What is Tango Therapeutics Inc. insider trading activity?

View the latest insider trading data for Tango Therapeutics Inc. on Alpha Lenz.

What is Tango Therapeutics Inc.'s P/E ratio?

Tango Therapeutics Inc.'s P/E ratio is -29.6.

Tango Therapeutics Inc.

NASDAQ · TNGX

$25.85-0.80(-3.00%)Pre-market

Ask about Tango Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Tango Therapeutics Inc. trades at a P/E of -29.6 (undervalued) with modest ROE of -37.2%. 3Y revenue CAGR of 35.9% highlights clear growth momentum.”

Ask for details →

Company Overview

Tango Therapeutics Inc. is a biotechnology company that focuses on the discovery and development of precision cancer medicines. Its primary objective is to identify novel therapeutic targets and develop treatments based on synthetic lethality, an approach that exploits vulnerabilities within cancer cells for effective treatment. Tango Therapeutics operates in the biotechnology and healthcare sectors, impacting areas such as cancer research, drug development, and personalized medicine. The company harnesses advanced technologies in genomics and bioinformatics to uncover potential drug candidates that are specifically tailored to the genetic profile of different cancer types. Tango Therapeutics plays a crucial role in the treatment landscape by providing innovative solutions that are designed to improve outcomes for cancer patients. Established as a leader in precision oncology, the company contributes to the growing field of targeted therapies, aiming to transform how cancer is treated across the globe.

CEODr. Barbara L. Weber M.D.

Websitehttps://www.tangotx.com

SectorHealthcare

IndustryBiotechnology

Employees155

Company Statistics

FY 2025

Profile

$3.00BMarket Cap

$62.38MRevenue

0.00Shares Out

155Employees

Margins

N/AGross

-174.74%EBITDA

-178.39%Operating

-162.85%Pre-Tax

-162.85%Net

Valuation

-29.56P/E

8.67P/B

48.14EV/Sales

-26.83EV/EBITDA

-21.46P/FCF

Growth (CAGR)

35.89%Rev 3Yr

52.13%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-28.41%ROA

-37.23%ROE

-31.12%ROIC

Financial Health

$112.28MCash & Cash Equivalents

$-59.77MNet Debt

15.17%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Tango Therapeutics Inc. trades at a P/E of -29.6 (undervalued) with modest ROE of -37.2%. 3Y revenue CAGR of 35.9% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Tango Therapeutics Inc. (ticker: TNGX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 155 employees. Market cap is $3.0B.

The current price is $25.85 with a P/E ratio of -29.56x and P/B of 8.67x.

ROE is -37.23% and operating margin is -178.39%. Annual revenue is $62M.